Cambridge Biomedical Inc announces Collaboration with XenTech SAS

Monday, January 19, 2015

Cambridge Biomedical Inc announces collaboration with XenTech SAS based in Evry, France to jointly market CRO services to the biotech and pharmaceutical market in the USA and Europe.

Dr. John Reddington, COO of Cambridge Biomedical, commented that “XenTech’s patient-derived primary tumor Xenograft models combined with the experience of Cambridge Biomedical in bioanalytical assay development enables us to provide a cohesive offering from Development through to Phase IV. This collaboration further enables us to provide critical solutions to meet the product development needs of our partners in the burgeoning healthcare community.”

“Cambridge Biomedical and XenTech have the same scientific DNA,” commented Dr. Pascal Leuraud, XenTech Chief Operating Officer.

“This mean that for both partners, the quest for best science drives our CRO activity,” he said.

“We believe this collaboration will open up access to new customers in both the biotech and pharma sectors and allow both partners to cross-fertilize our customer portfolios in the US and Europe,” said Dr. Leuraud.

 

Source : http://www.prweb.com/